CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
滑膜肉瘤患者在接受 MAGE A4 过继细胞治疗前进行淋巴细胞清除后发生 EB 病毒阳性淋巴增殖性疾病：一例病例报告
英文原题：Epstein Barr Virus-Positive Lymphoproliferative Disorder Following Lymphodepletion for MAGE A4 Adoptive Cellular Therapy in a Patient with Synovial Sarcoma: A Case Report.
查看英文原题
Epstein Barr Virus-Positive Lymphoproliferative Disorder Following Lymphodepletion for MAGE A4 Adoptive Cellular Therapy in a Patient with Synovial Sarcoma: A Case Report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
与病毒再激活相关的淋巴增殖性疾病（LPD）是免疫功能低下患者已知的风险。随着利用淋巴细胞清除方案的晚期癌症新型细胞疗法的发展，LPD的风险应予以考虑。在此，我们报告一例61岁男性患者，有转移性滑膜肉瘤病史并接受过多线治疗，在临床研究中接受细胞疗法（淋巴细胞清除性化疗和afami-cel，原为ADP-A2M4，T细胞治疗）后发生了Epstein Barr病毒阳性LPD。患者接受rituximab治疗并获得完全缓解。新型细胞疗法为患者提供了有前景的治疗选择，应仔细监测不良事件。
展开英文摘要原文
Lymphoproliferative disorder (LPD) associated with viral reactivation is a known risk of immunocompromised patients. With development of novel cellular therapies utilizing lymphodepletion regimens in advanced cancer, the risk of LPDs should be a consideration.
Here, we report a case of a 61-year-old treated male with history of metastatic synovial sarcoma and multiple treatment lines treated with cell therapy (lymphodepleting chemotherapy and afami-cel, formerly ADP-A2M4, T-cell treatment) on clinical study that developed Epstein Barr virus-positive LPD. Patient was treated with rituximab and achieved a complete response. New cellular therapies present promising treatment options for patients and adverse events should be monitored carefully.
论文信息
- 作者
- Zhou M、Jawed G、Ganjoo KN
- 单位
- Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA, USA.United States
- 文献类型
- 病例报告
- 期刊
- Case reports in oncology2023 Jan-Dec
- 原文标识
- PubMed 37900845 · DOI 10.1159/000533129
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →